Lantern Pharma (NASDAQ:LTRN) Downgraded by Wall Street Zen to Sell

Lantern Pharma (NASDAQ:LTRN) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lantern Pharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Lantern Pharma has an average rating of “Hold” and a consensus target price of $25.00.

Lantern Pharma Trading Up 1.0%

NASDAQ LTRN opened at $4.01 on Friday. The stock has a market capitalization of $43.31 million, a price-to-earnings ratio of -2.25 and a beta of 1.57. The stock has a 50-day moving average of $4.16 and a 200 day moving average of $3.88. Lantern Pharma has a twelve month low of $2.55 and a twelve month high of $6.12.

Lantern Pharma (NASDAQ:LTRN) last released its earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.13. Equities analysts predict that Lantern Pharma will post -1.9 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantern Pharma

An institutional investor recently bought a new position in Lantern Pharma stock. XTX Topco Ltd bought a new stake in Lantern Pharma Inc. (NASDAQ:LTRN) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 12,624 shares of the company’s stock, valued at approximately $40,000. XTX Topco Ltd owned about 0.12% of Lantern Pharma at the end of the most recent quarter. Hedge funds and other institutional investors own 28.62% of the company’s stock.

About Lantern Pharma

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.